Twenty years of medical determination, the combination of Chinese and Western medicine for the benefit of Sangzi.

Release time:

Sep 28,2020


Summary:Zhang Jun, Chairman of Dalian Aili Health Recovery Hospital Co., Ltd., Chairman of Sub-health Pathology Research Center, and Vice Chairman of Hong Kong Zhang Xueliang Foundation. Zhang Jun has been engaged in the research of brain diseases for many years. Using the theory of meridians and collaterals of traditional Chinese medicine and wavelength of western medicine, Zhang Jun pioneered the "Ailijian" therapy to repair human cells without trauma. He successfully cured Parkinson's syndrome, cerebral atrophy, cerebellar atrophy, stroke sequelae, diabetes type 2, autism and bone degeneration, tinnitus, etc. He is a legendary figure in the medical field and enjoys a high reputation in the international medical field.


Related News


Honored as the cover person of 2017

Zhang Jun, Chairman of the Group, was interviewed by the China Cultural Information Association (under the Ministry of Culture of China).

Twenty years of medical determination, the combination of Chinese and Western medicine for the benefit of Sangzi.

Zhang Jun, Chairman of Dalian Aili Health Recovery Hospital Co., Ltd., Chairman of Sub-health Pathology Research Center, and Vice Chairman of Hong Kong Zhang Xueliang Foundation. Zhang Jun has been engaged in the research of brain diseases for many years. Using the theory of meridians and collaterals of traditional Chinese medicine and wavelength of western medicine, Zhang Jun pioneered the "Ailijian" therapy to repair human cells without trauma. He successfully cured Parkinson's syndrome, cerebral atrophy, cerebellar atrophy, stroke sequelae, diabetes type 2, autism and bone degeneration, tinnitus, etc. He is a legendary figure in the medical field and enjoys a high reputation in the international medical field.

Hospital News


Interview with CCTV

Chairman Zhang Jun was also invited by CCTV, as a representative of China Rehabilitation Hospital, to receive an exclusive interview with the "pilot" program.
Return